TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

ETAS ID: TM460456

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Oxford Finance Corporation		01/29/2018	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	Titan Pharmaceuticals, Inc.
Street Address:	400 OYSTER POINT BOULEVARD
Internal Address:	SUITE 505
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 3

Property Type	Number	Word Mark
Serial Number:	76281064	PROBUPHINE
Serial Number:	75455716	ССМ
Serial Number:	75146837	SPHERAMINE

CORRESPONDENCE DATA

Fax Number: 3124643111

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212.407.4000

Email: chicagopto@loeb.com

Kathleen Gersh c/o Loeb & Loeb LLP **Correspondent Name:**

Address Line 1: 345 Park Avenue

Address Line 4: New York, NEW YORK 10154

NAME OF SUBMITTER:	Kathleen Gersh
SIGNATURE:	/Kathleen Gersh/
DATE SIGNED:	02/01/2018

Total Attachments: 4

900437807

source=Titan - Release of Security Agreement - Oxford Corp - Executed#page1.tif source=Titan - Release of Security Agreement - Oxford Corp - Executed#page2.tif source=Titan - Release of Security Agreement - Oxford Corp - Executed#page3.tif

> **TRADEMARK** REEL: 006263 FRAME: 0563

source=Titan - Release of Security Agreement - Oxford Corp - Executed#page4.tif

TRADEMARK REEL: 006263 FRAME: 0564



RELEASE OF SECURITY AGREEMENT COVERING INTERESTS IN TITAN PHARMACEUTICALS, INC.

Oxford Finance Corporation ('Secured Party'), hereby releases its security interest in the interests of Titan Pharmaceuticals, Inc. in Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto) and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds from infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisionals, continuations, renewals, extensions and continuations-in-part thereof created by that certain Intellectual Property Security Agreement executed by Titan Pharmaceuticals, Inc. in favor of Secured Party recorded with the United States Patent and Trademark Office at Reel/Frame 023699/0096.

Dated:	January 29, 2018	Oxford Finance Corpo	Oxford Finance Corporation		
		~ 1 1	1		

Name:

Senior Vice President

Title:

EXHIBIT A

Copyrights

Description

Registration Number Registration Date

None.

WEST/21840263.2 368986-000020

PATENT

REEL: 023699 FRAME: 0101

REEL: 006263 FRAME: 0566

EXHIBIT B

Patents

Description	Patent/App. No.	File Date
1. Use of gallium to treat biofilm-associated infections	11700289	1/30/07
2. Implantable polymeric device for sustained release of buprenorphine	10453377	6/2/03
3. Combination of chemotherapeutic drugs for increasing antitumor activity	10521548	8/22/05
4. Implantable polymeric device for sustained release of dopamine agonist	10815481	3/31/04
5. Implantable polymeric device for sustained release of nalmefene	10856178	5/27/04
6. Use of gallium to treat inflammatory arthritis	11015172	12/17/04
7. Use of pigmented retinal epithelial cells for creation of an immune privilege site	11363911	2/27/06
8. Methods of treating schizophrenia	11497914	8/1/06
9. Treatment and prevention of adverse liver conditions using gallium	11594582	11/7/06
10. Implantable polymeric device for sustained release of buprenorphine	11801302	5/8/07
11. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst	11805608	5/23/07
12. Implantable polymeric device for sustained release of dopamine agonist	12119334	5/12/08
13. Method for gene transfer to the central nervous system	6210664	4/3/01
14. Methods of treating schizophrenia	7115256	10/3/06

WEST\21840263.2 368986-000020

PATENT

REEL: 023699 FRAME: 0102

REEL: 006263 FRAME: 0567

EXHIBIT C

Trademarks

Description	Serial/Registration		
	<u>No.</u>	File Date	
I. PROBUPHINE	76281064	7/6/01	
2. CCM	75455716	3/24/98	
3. SPHERAMINE	75146837	8/8/96	

WEST\21840263.2 368986-000020

RECORDED: 12/23/2009

RECORDED: 02/01/2018

5

PATENT

REEL: 023820 DEMANEK 0103

REEL: 006263 FRAME: 0568